Inactive Instrument

Theradiag

Equities

ALTER

FR0004197747

15/04/2021 : Mise à disposition du Rapport Financier annuel 2020 (only available in French)

April 15, 2021 at 02:35 pm EDT

Croissy-Beaubourg, le 15 avril 2021, 17h45 CEST - THERADIAG (ISIN : FR0004197747, Mnémonique : ALTER), société spécialisée dans le diagnostic in vitro et le théranostic annonce aujourd'hui que son rapport financier semestriel au 31 décembre 2020 a été mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers.

Il est disponible sur le site de THERADIAG, www.theradiag.com, dans la rubrique Investisseurs / Actualités financières / Rapports Financiers ainsi que sur le site de l'AMF www.amf-france.org.

Attachments

Original document
Permalink

Disclaimer

Theradiag SA published this content on 15 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2021 18:34:04 UTC.

Latest news about Theradiag

Biosynex: merger with Theradiag completed	Dec. 18	CF
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Theradiag SA Reports Audited Revenue Results for the Second Quarter and First Half Ended on June 30, 2023	23-07-17	CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Theradiag SA Announces Executive Changes	23-03-01	CI
Theradiag SA Announces Management Changes	23-03-01	CI
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Theradiag SA Announces Revenue Results for the Year Ended December 31, 2022	23-01-16	CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA.	23-01-11	CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag	22-09-23	MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA.	22-09-22	CI
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Theradiag SA Announces Revenue Results for the Six Months Ended June 30, 2022	22-07-18	CI
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics	22-06-08	CI
Theradiag Announces the Launch of ez-Track, A Point-Of-Care Testing Solution for Therapeutic Drug Monitoring	22-05-31	CI
THERADIAG Announces the Launch of Two New i-Tracker® Kits	22-05-19	CI
Theradiag Announces Executive Changes	22-05-06	CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-08	CI
Theradiag Signs PCR Test Distribution Agreement With Biosynex	22-01-13	MT
Theradiag Announces Signing of A Distribution Agreement with Biosynex of Their AMPLIQUICK SARS-CoV-2 PCR Test	22-01-13	CI
THERADIAG Announces the Launch of 4 New i-Tracker? Kits and the Validation of a New Parameter in the United States	21-12-02	CI
France's Biosynex Raises Theradiag Stake to Nearly 19%	21-11-30	MT
Theradiag Raises $5 Million Via Rights Issue To Fund Expansion	21-11-24	MT
Theradiag Slumps 21% on Launch of $6 Million Rights Issue	21-10-26	MT
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-19	CI

Chart Theradiag

Duration

Period

More charts

Company Profile

Theradiag develops, produces, and sells in vitro diagnostic kits for detecting auto-immune diseases, allergies, and infectious diseases. The group also offers theranostic tests for monitoring biotherapies and determining patient response to treatments applied. 54.6% of net sales are abroad.

Sector

More about the company